LIFECORE BIOMEDICAL, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
LIFECORE BIOMEDICAL, INC. (LFCR) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$16.23 million for the 3-month period ending 2024-08-25, per its 10-Q filed 2024-10-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2024-10-04
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-08-25 was -$16.23M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-05-26 was -$7.09M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-02-25 was $14.79M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-11-26 was $14.24M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $9.33M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$64.24M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$15.48M.
- LIFECORE BIOMEDICAL, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$23.44M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-08-25 | -$16.23M 10-Q · filed 2024-10-04 | -$23.32M derived: sum of 2 quarters · filed 2024-10-04 | -$8.53M derived: sum of 3 quarters · filed 2024-10-04 | $5.71M derived: sum of 4 quarters · filed 2024-10-04 | ||||
| 2024-05-26 | -$7.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $7.70M derived: sum of 2 quarters · filed 2024-08-26 | $21.94M derived: sum of 3 quarters · filed 2024-08-26 | $9.33M 10-K · filed 2024-08-26 | ||||
| 2024-02-25 | $14.79M 10-Q · filed 2024-08-09 | $29.03M derived: sum of 2 quarters · filed 2024-08-09 | $16.42M 10-Q · filed 2024-08-09 | -$20.58M derived: sum of 4 quarters · filed 2024-10-04 | ||||
| 2023-11-26 | $14.24M 10-Q · filed 2024-08-09 | $1.63M 10-Q · filed 2024-08-09 | -$35.37M derived: sum of 3 quarters · filed 2024-10-04 | -$46.70M derived: sum of 4 quarters · filed 2024-10-04 | ||||
| 2023-08-27 | -$12.61M 10-Q · filed 2024-10-04 | -$49.61M derived: sum of 2 quarters · filed 2024-10-04 | -$60.94M derived: sum of 3 quarters · filed 2024-10-04 | -$70.14M derived: sum of 4 quarters · filed 2024-10-04 | ||||
| 2023-05-28 | -$37.00M 10-K · filed 2024-03-20 | -$48.33M derived: sum of 2 quarters · filed 2024-08-09 | -$57.53M derived: sum of 3 quarters · filed 2024-08-09 | -$64.24M 10-K · filed 2024-08-26 | ||||
| 2023-02-26 | -$11.33M 10-Q · filed 2024-08-09 | -$15.46M 10-Q · filed 2023-06-02 | -$20.53M derived: sum of 2 quarters · filed 2024-08-09 | -$27.24M 10-Q · filed 2024-08-09 | -$34.71M 10-Q · filed 2023-06-02 | -$30.87M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2022-11-27 | -$9.20M 10-Q · filed 2024-08-09 | -$12.45M 10-Q · filed 2023-03-16 | -$15.91M 10-Q · filed 2024-08-09 | -$23.80M 10-Q · filed 2023-03-16 | -$19.54M derived: sum of 3 quarters · filed 2024-08-09 | -$30.46M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2022-08-28 | -$6.71M 10-Q · filed 2024-08-09 | -$12.06M 10-Q · filed 2022-10-07 | -$10.34M derived: sum of 2 quarters · filed 2024-08-09 | -$21.26M derived: sum of 3 quarters · filed 2024-08-09 | -$13.71M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2022-05-29 | -$3.63M 10-K · filed 2024-03-20 | -$34.44M 10-K · filed 2022-09-14 | -$14.55M derived: sum of 2 quarters · filed 2024-03-20 | -$7.00M derived: sum of 3 quarters · filed 2024-03-20 | -$15.48M 10-K · filed 2024-08-26 | -$46.28M 10-K · filed 2022-09-14 | ||
| 2022-02-27 | -$10.92M 10-K · filed 2024-03-20 | -$7.11M 10-Q · filed 2022-04-07 | -$3.37M derived: sum of 2 quarters · filed 2024-03-20 | -$11.38M 10-Q · filed 2023-06-02 | -$10.51M 10-Q · filed 2022-04-07 | -$12.63M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-11-28 | $7.55M 10-K · filed 2024-03-20 | $3.67M 10-K · filed 2022-09-14 | -$3.40M 10-Q · filed 2023-03-16 | -$1.71M derived: sum of 3 quarters · filed 2024-03-20 | -$3.46M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-08-29 | -$8.47M 10-K · filed 2024-03-20 | -$7.21M 10-K · filed 2022-09-14 | -$9.25M derived: sum of 2 quarters · filed 2024-03-20 | -$11.00M derived: sum of 3 quarters · filed 2024-03-20 | -$19.39M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-05-30 | -$780.00K 10-K/A · filed 2023-03-16 | -$2.87M 10-K · filed 2021-07-29 | -$2.53M derived: sum of 2 quarters · filed 2024-03-20 | -$10.92M derived: sum of 3 quarters · filed 2024-03-20 | -$23.44M 10-K · filed 2024-03-20 | -$32.66M 10-K · filed 2021-07-29 | ||
| 2021-02-28 | -$1.75M 10-K · filed 2024-03-20 | -$5.50M 10-K · filed 2021-07-29 | -$10.14M derived: sum of 2 quarters · filed 2024-03-20 | -$8.79M 10-Q · filed 2022-04-07 | -$35.28M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2020-11-29 | -$8.39M 10-K · filed 2024-03-20 | -$13.30M 10-K · filed 2021-07-29 | -$18.38M derived: sum of 2 quarters · filed 2024-03-20 | -$33.53M derived: sum of 3 quarters · filed 2024-03-20 | -$45.05M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2020-08-30 | -$9.99M 10-K · filed 2024-03-20 | -$11.00M 10-K · filed 2021-07-29 | -$25.14M derived: sum of 2 quarters · filed 2024-03-20 | -$36.66M derived: sum of 3 quarters · filed 2024-03-20 | -$43.40M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2020-05-31 | -$15.15M 10-K · filed 2021-07-29 | -$26.67M derived: sum of 2 quarters · filed 2021-07-29 | -$33.41M derived: sum of 3 quarters · filed 2021-07-29 | -$21.87M 10-K/A · filed 2023-03-16 | -$38.19M 10-K · filed 2020-08-14 | |||
| 2020-02-23 | -$11.52M 10-K · filed 2021-07-29 | -$18.26M derived: sum of 2 quarters · filed 2021-07-29 | -$23.04M derived: sum of 3 quarters · filed 2021-07-29 | -$22.68M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-11-24 | -$6.74M 10-K · filed 2021-07-29 | -$11.52M derived: sum of 2 quarters · filed 2021-07-29 | -$11.16M derived: sum of 3 quarters · filed 2021-07-29 | -$9.62M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-08-25 | -$4.78M 10-K · filed 2021-07-29 | -$4.42M derived: sum of 2 quarters · filed 2021-07-29 | -$2.88M derived: sum of 3 quarters · filed 2021-07-29 | -$3.00M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2019-05-26 | $367.00K 10-K · filed 2020-08-14 | $1.90M derived: sum of 2 quarters · filed 2020-08-14 | $1.79M derived: sum of 3 quarters · filed 2020-08-14 | $2.12M 10-K · filed 2021-07-29 | ||||
| 2019-02-24 | $1.53M 10-K · filed 2020-08-14 | $1.07M 10-Q · filed 2019-04-04 | $1.42M derived: sum of 2 quarters · filed 2020-08-14 | $672.00K 10-Q · filed 2019-04-04 | $8.47M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2018-11-25 | -$113.00K 10-K · filed 2020-08-14 | -$584.00K 10-Q · filed 2019-01-07 | -$395.00K 10-Q · filed 2019-01-07 | $6.93M derived: sum of 3 quarters · filed 2020-08-14 | $23.21M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2018-08-26 | $335.00K 10-K · filed 2020-08-14 | $190.00K 10-Q · filed 2018-10-05 | $7.05M derived: sum of 2 quarters · filed 2020-08-14 | $23.33M derived: sum of 3 quarters · filed 2020-08-14 | $23.74M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2018-05-27 | $6.71M 10-K · filed 2019-08-01 | $22.99M derived: sum of 2 quarters · filed 2019-08-01 | $23.41M derived: sum of 3 quarters · filed 2019-08-01 | $25.76M 10-K · filed 2020-08-14 | ||||
| 2018-02-25 | $16.28M 10-K · filed 2019-08-01 | $16.70M derived: sum of 2 quarters · filed 2019-08-01 | $19.05M 10-Q · filed 2019-04-04 | $21.65M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2017-11-26 | $414.00K 10-K · filed 2019-08-01 | $2.77M 10-Q · filed 2019-01-07 | $5.37M derived: sum of 3 quarters · filed 2019-08-01 | $8.96M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2017-08-27 | $2.35M 10-K · filed 2019-08-01 | $4.95M derived: sum of 2 quarters · filed 2019-08-01 | $8.54M derived: sum of 3 quarters · filed 2019-08-01 | $9.31M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2017-05-28 | $2.60M 10-K · filed 2018-08-09 | $6.19M derived: sum of 2 quarters · filed 2018-08-09 | $6.95M derived: sum of 3 quarters · filed 2018-08-09 | $10.13M 10-K · filed 2019-08-01 | ||||
| 2017-02-26 | $3.59M 10-K · filed 2018-08-09 | $4.36M derived: sum of 2 quarters · filed 2018-08-09 | $7.54M derived: sum of 3 quarters · filed 2018-08-09 | |||||
| 2016-11-27 | $765.00K 10-K · filed 2018-08-09 | $3.95M derived: sum of 2 quarters · filed 2018-08-09 | ||||||
| 2016-08-28 | $3.18M 10-K · filed 2018-08-09 | |||||||
| 2016-05-29 | -$11.99M 10-K · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |